Kanwal Raghav, MBBS, MD, discusses factors that should be considered when deciding on treatment for a patient with metastatic colorectal cancer.
Kanwal Raghav, MBBS, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses factors that should be considered when deciding on treatment for a patient with metastatic colorectal cancer (mCRC).
Regorafenib (Stivarga) and TAS-102 are both targeted therapies used for the treatment of mCRC. Raghav explains that no rationale exists for the use of one therapy over the other because the clinical trial research supporting these agents was performed in the same patient population. However, there are some differences in how the agents are utilized, says Raghav. For example, oncologists tend to administer regorafenib before TAS-102.
There are other clinical trials for both regorafenib and TAS-102 to determine the activity of the agents in combination with other drugs. Research has already demonstrated the TAS-102 has efficacy in patients who have developed resistance to regorafenib and that regorafenib can be a bridge o TAS-102 therapy. It has also been shown that these agents have different toxicity profiles, and for TAS-102, some may be dose-limiting.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More